FDA approved for the treatment of metastatic melanoma harboring activating BRAF mutations in August, 2011. Vemurafenib is metabolized by cytochrome P450 isoenzymes (predominantly CYP3A4 ...

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 ...

“Those of us in the melanoma business have felt like we've ... specifically inhibits the V600E mutant BRAF, a constitutively active kinase present in more than half of metastatic melanomas.

This is also called BRAF wild type. If you have changes in the BRAF gene, doctors describe the melanoma as BRAF positive. This is also called BRAF mutated. Or you might have targeted cancer drugs ...

Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer ...

The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...

BRAF, a member of a serine/threonine kinase ... MAPK pathway inhibitors are currently utilized for the therapy of malignant metastatic melanoma. They include RAF inhibitors, such as sorafenib ...

BRAF and MEK inhibitors used to treat melanoma (skin cancer) with a BRAF gene mutation (present in 50% of melanoma cases), and PARP and PD-L1 inhibitors intended for breast cancer with a BRCA gene ...

The BRAF Inhibitors market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer, rise in biomarker testing rates, the ...

In patients with BRAF V600E-mutant metastatic colorectal cancer, a combination of encorafenib, cetuximab, and mFOLFOX6 chemotherapy showed a 60.9% overall response rate, outperforming the 40% ...